Jubilant Ingrevia Ltd. · NSE:JUBLINGREA
Jubilant Ingrevia — Q1 FY26 Earnings Presentation
44 slides from Jubilant Ingrevia's earnings presentation, Jul 31, 2025
Slide 1: Cover letter to BSE and NSE
July 31, 2025 BSE Limited National Stock Exchange of India Limited Floor 25, P. J. Towers Exchange Plaza Dalal Street, Fort Bandra Kurla Complex Mumbai - 400 001 Bandra (E), Mumbai - 400 051 Scrip Code: 543271 Trading Symbol: JUBLINGREA Sub: Press Release and presentation on the financials and opera
Slide 2: Jubilant Ingrevia Limited – Q1'FY26 Results
Jubilant Ingrevia Limited 1A, Sector 16A, Noida – 201301, India Tel.: +91 120 4361000 PRESS RELEASE www.jubilantingrevia.com Noida, Tuesday, July 31st, 2025 JUBILANT INGREVIA LIMITED – Q1’FY26 RESULTS 1 Particulars Q1'FY25 Q4'FY25 Q1'FY26 Q-o-Q Y-o-Y Total Revenue 1,024 1,051 1,038 -1% 1% Total EBIT
Slide 3: Future Outlook and management commentary
saw sustained YoY growth, and the EU’s anti-dumping duty on China is expected to strengthen Jubilant’s position in Choline Chloride market. We are already in touch with multiple EU customers for choline chloride sales. In Chemical Intermediates segment, our strategic push towards Ethyl Acetate, led
Slide 4: Management commentary on R&D and Nutrition
and demand. To support this momentum, we have made strategic investments in R&D and established a dedicated team focused on advancing our capabilities and offerings in this space. d) Under our Nutrition business, we continued to maintain our leadership position in Vitamin B3, particularly in the ani
Slide 5: Q1'FY26 Highlights | Segment Wise Analysis
d) The commissioning of the new boiler at our Bharuch facility is scheduled for Q2 of FY26, with more than 99% work already completed. e) In addition, debottlenecking initiatives are actively underway to unlock additional capacity across our core platforms, including diketene and pyridine. f) We hav
Slide 6: Nutrition & Health Solutions; Chemical Intermediates
B. Nutrition & Health Solutions 1 Particulars Q1'FY25 Q4'FY25 Q1'FY26 Q-o-Q Y-o-Y Segment Revenue 186 190 179 -6% -4% % Share of Overall Revenue 18% 18% 17% EBITDA 23 29 25 -16% 8% % EBITDA Margin 12% 16% 14% % Contribution to EBITDA 2 16% 17% 14% 1. All figures are in Rs Crore unless otherwise stat
Slide 7: Income Statement – Q1'FY26
Cost - Acetic Acid prices declined marginally during the quarter - Through ongoing cost optimization measures and easing freight rates, margin expansion expected in few quarters Price - Segment prices remained steady on a sequential basis Business Drivers - Revenue improved QoQ, supported by an incr
Slide 8: Segment P&L and Debt Position
4. Segment P&L – Q1’FY26 Particulars1 Q1'FY25 Q4'FY25 Q1'FY26 QoQ (%) YoY (%) Revenue Speciality Chemicals 431 487 478 (2%) 11% Nutrition & Health Solutions 186 190 179 (6%) (4%) Chemical Intermediates 408 375 381 2% (7%) Total Revenue from Operations 1,024 1,051 1,038 (1%) 1% Reported EBITDA 119 15
Slide 9: About Jubilant Ingrevia Limited
About Jubilant Ingrevia Limited Jubilant Ingrevia Limited is a globally integrated Life Sciences & Specialty Chemicals company, serving Pharmaceutical, Nutrition, Agrochemical, Consumer and Industrial customers. It has a broad portfolio of over 130+ products and customised solutions that are innovat
Slide 10: Earnings Call details
Earnings Call details: The company will host earnings call at 5.00 PM IST on 31st July, 2025 Diamond Pass Log-In To enable participants to connect to the conference call without having to wait for an operator, please register at the below mentioned link. Pre-registration: You will receive dial in nu
Slide 11: Investor Presentation
Investor Presentation July 2025 Innovating for a Sustainable Future 1
Slide 12: Disclaimer
Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product
Slide 13: Management statement and markets update
“We are pleased to present the financial results for the first quarter of this fiscal year. Our specialty chemical businesses have continued to perform strongly, growing double digit YoY and with stable performance on QoQ basis. Our Chemical Intermediates business has started to recover marginally w
Slide 14: Business Update
Business Update: Specialty Chemicals saw stable volumes, with growth led by Pyridine and Diketene derivatives and CDMO sales. Pharma end-use sales posted strong YoY demand growth with steady pricing. Agriculture end-use segment showed modest volume gains, stable pricing, and normalized inventories.
Slide 15: Table of Contents
Table of Contents 0 6 Company Overview 1 3 Growth Roadmap 1 8 Q1’FY26 Highlights 2 5 Business Segments Update 5
Slide 16: Company Overview
Company Overview . Visuals of our New Diketene Derivatives Plant in Gajraula 6
Slide 17: Transformation into Specialty Leader
Transformation into Forward Specialty Leader Expansion & Integration 2023 onwards Origin Diversification 2011 - 2023 1978 – 1990 1990 – 2011 • Expansion of Pyridine • Started as VAM • Forward integration into • Foray into Pyridine derivatives Organics Pyridine derivatives Chemistry • Foray into Dike
Slide 18: Business segments and global leadership positions
1 2 3 Specialty Nutrition Chemical Chemicals & Health Solutions Intermediates • CDMO • Fine Chemicals • Animal Nutrition and Health Solutions • Acetic Anhydride • Acetaldehyde • Pyridine and Picolines • Human Nutrition Solutions • Ethyl Acetate • Bio Acetic Acid Globally #1 Globally #2 Globally #2 •
Slide 19: Revenue mix by segment, end-use and geography
Consumer ROW Nutrition 5% 13% & Health Agro North Solutions 18% Pharma America 17% Specialty 32% 10% India Chemicals 56% 46% Europe Chemical Industrial 21% Intermediates 26% 37% Nutrition 17% 9
Slide 20: Facilities and operational capabilities
Gajraula Bharuch Nira Savli Ambernath Uttar Pradesh, India Gujarat, India Maharashtra, India Gujarat, India Maharashtra, India Integrated facility for CDMO & Fine Chemicals Chemical Intermediates Animal Nutrition Microbial Control Specialty Chemicals & Nutrition and Chemical Facility & Health Soluti
Slide 21: R&D Centers, Scientists, PhDs
R&D Center G. Noida UP, India Pilot Plant at Gajraula UP, India 3 ~150 ~30 R&D Centers Scientists PhDs 11
Slide 22: Leadership team
SS Bhartia HS Bhartia Deepak Jain Chairman Co-Chairman & Whole CEO & MD Time Director 20 yrs exp Business Leaders Function Leaders Specialty Chemicals Nutrition & Health Chemical Intermediates Varun Gupta Vijay Kumar Srivastava Ambrish Dixit Ashish Kr. Sinha Himanshu Dhapola President, Chief Preside
Slide 23: Growth Roadmap
Growth Roadmap (Recap and Progress Update) 13
Slide 24: Pinnacle 3.4.5 growth path
We set out on an ambitious growth path — Pinnacle 345 wan INGREVIA & _—_—- uu, AD —-— times 5 Al times Kin year "All REVENUE EBITDA HORIZON
Slide 25: Pinnacle growth pillars
PINNACLE3.4.5 PINNACLE 3.4.5 G R O W T H P I L L A R S New Growth Areas A Specialty Chemicals B Nutrition & Health solutions C Chemical Intermediates Pyridine & Picoline Animal Nutrition Acetic Anhydride Retain Global leadership (#1 position, cost leadership) Scale up Oilfield chemicals Feed Vit B3:
Slide 26: Today, Business, Tomorrow: Key Achievements
Today Business Tomorrow Key Achievements • Maintained global leadership and market share in Pyridine and Beta-Picoline Pyridine & Picoline • Increased SOW in AP/APQ across customers • 15%+ revenue growth in FY25; Maintained leadership across 36 Pyridine Derivatives • Good traction in Diketene Deriva
Slide 27: Today, Pillars, Tomorrow quarterly progress
Today Pillars Tomorrow Q1FY25 Q2FY25 Q3FY25 A Q4FY25 Q1FY26 Roadshows across EU/ Secured CDMO order Secured CDMO order Funnel expansion across In-process of launching of US/ Japan; 120+ from Agro Innovator #1 from Agro Innovator #2 Pharma/Agro/Semicon Human Nutrition pre-mixes Customer customer meet
Slide 28: Q1'FY26 Highlights
Q1’FY26 Highlights 18 18
Slide 29: End-use market updates: Pharma, Agrochem, Nutrition
PHARMA • Volumes remained steady across segments, especially in our core products in Fine Chemicals • The paracetamol segment remained muted given the low demand and utilization levels. • Prices remain stable (vs Q4’FY25) across various segments; Customers awaiting clarity on tariff situation AGROCH
Slide 30: Core product platforms continue to drive performance
• Pyridine & Picoline: Globally #1 position in P&P (only scaled non-Chinese player), QoQ volume Core product platforms continue to growth driving overall sales growth despite some price volatility drive performance; Acetyls portfolio • Niacinamide: Maintained leadership position in feed grade with i
Slide 31: Revenue & EBITDA drivers
Particulars1 Q1'FY25 Q4'FY25 Q1'FY26 Q-o-Q Y-o-Y Total Revenue 1,024 1,051 1,038 -1% 1% Total EBITDA 119 155 153 -1% 29% EBITDA Margin (%) 12% 15% 15% Profit After Tax 49 74 75 1% 54% Profit After Tax Margin (%) 5% 7% 7% Basic and Diluted EPS (Rs.) 3.1 4.7 4.7 1% 54% Revenue & EBITDA during the quar
Slide 32: JVL EBITDA Key Drivers
JVL EBITDA Key Drivers 35.0% 153 160 151 30.0% 140 • Increasing revenue share of Specialty Chem + 125 Nutrition BUs 25.0% 119 120 • Increasing share of high-value products within 20.0% each BU portfolio e.g., increasing share of 100 14.8% 15.0% 13.0% cosmetic/food grade B3, higher growth from new 11
Slide 33: Segment-wise EBITDA Share (%)
Segment-wise EBITDA Share (%) 6% 13% 10% 25% 27% 17% 36% 36% 14% 43% 40% 15% 48% 46% 45% 49% 16% 16% 7% 14% 5% 14% 8% 4% 13% 12% 76% 76% 72% 56% 59% 57% 52% 50% 46% 47% 46% 40% 43% Q1FY23 Q2FY23 Q3FY23 Q4FY23 Q1FY24 Q2FY24 Q3FY24 Q4FY24 Q1FY25 Q2FY25 Q3FY25 Q4FY25 Q1FY26 Specialty Chemicals Nutritio
Slide 34: Segment EBITDA and margins
Specialty Chemicals Nutrition Chemical Intermediates EBITDA (Rs Cr.) EBITDA (Rs Cr.) EBITDA (Rs Cr.) Y.o.Y Growth 52% Y.o.Y Growth 8% Y.o.Y Growth -53% Q.o.Q Growth 1% Q.o.Q Growth -16% Q.o.Q Growth 63% 129 130 29 36 25 23 86 27% 27% 16% 17 14% 20% 12% 10 9% 4.4% 2.6% Q1 FY25 Q4 FY25 Q1 FY26 Q1 FY25
Slide 35: Business Segments Overview
Business Segments Overview 25
Slide 36: Specialty Chemicals: Pharma, Agrochemical, CDMO
1 MARKET HIGHLIGHTS FINANCIAL HIGHLIGHTS - Continued improvement in demand observed Particulars1 Q1'FY25 Q4'FY25 Q1'FY26 Q-o-Q Y-o-Y - YoY demand growth remained strong Segment Revenue 431 487 478 -2% 11% % Share of Overall Revenue 42% 46% 46% Pharma - Steady pricing trend maintained EBITDA 86 129 1
Slide 37: Nutrition & Health Solutions: Feed B3, Choline
2 MARKET HIGHLIGHTS FINANCIAL HIGHLIGHTS - Volumes were low as buyers delayed shipments, opting to maintain lower Particulars1 Q1'FY25 Q4'FY25 Q1'FY26 Q-o-Q Y-o-Y inventory levels Segment Revenue 186 190 179 -6% -4% Feed B3 - Overall Pricing witnessed modest softening % Share of Overall Revenue 18%
Slide 38: Chemical Intermediates: Volumes, Cost, Price
3 MARKET HIGHLIGHTS FINANCIAL HIGHLIGHTS - Acetic Anhydride volumes saw an uptick during Particulars1 Q1'FY25 Q4'FY25 Q1'FY26 Q-o-Q Y-o-Y the quarter driven by recovery in agrochem Segment Revenue 408 375 381 2% -7% segments - Ethyl Acetate volumes remained a key area of % Share of Overall Revenue 4
Slide 39: Annexures
Ww UBILANT Increvia VT Been lA Nn ita)
Slide 40: Income Statement
Particulars1 Q1'FY25 Q4'FY25 Q1'FY26 QoQ YoY Revenue from operations a) Sales/Income from operations 1010 1038 1029 -1% 2% b) Other operating income 14 13 9 -35% -39% Total revenue from operations 1024 1051 1038 -1% 1% Other income 10 8 11 34% 17% Total income 1034 1060 1049 -1% 1% Expenses a) Cost
Slide 41: Segment P&L
Particulars1 Q1'FY25 Q4'FY25 Q1'FY26 QoQ (%) YoY (%) Revenue Speciality Chemicals 431 487 478 (2%) 11% Nutrition & Health Solutions 186 190 179 (6%) (4%) Chemical Intermediates 408 375 381 2% (7%) Total Revenue from Operations 1,024 1,051 1,038 (1%) 1% Reported EBITDA 119 155 153 (1%) 29% Speciality
Slide 42: Debt Position
Particulars1 30-Jun-24 31-Mar-25 30-Jun-25 Long Term Borrowings 450 453 448 Short Term Borrowings 291 303 360 Total Gross Debt 741 756 808 Cash & Equivalent 64 98 107 Total Net Debt 677 658 700 YoY change 3% • The capex for the quarter was Rs 54 Crore, which was primarily utilized towards the upcomi
Slide 43: Earnings call details
Date : July 31st, 2025 Diamond Pass Log-In Time : 05:00 pm IST To enable participants to connect to the conference call without having to wait for an operator, please register at the below mentioned link. Pre-registration: You will receive dial in numbers, passcode and a pin for the concall on the r
Slide 44: Thank you for your time
Jubilant Ingrevia Limited is a globally integrated Life Sciences & For Investors: Specialty Chemicals company, serving Pharmaceutical, Nutrition, Agrochemical, Consumer and Industrial customers. It has a broad Pavleen Taneja portfolio of over 130+ products and customized solutions that are Jubilant